BRAF and neoplasm: Nowadays, the national comprehensive cancer network (NCCN) recommends tumor tissue genotyped for Ras-BRAF mutations in suspected or metastatic rectal cancers in order to tailor therapy and to confer – if any – benefit to patients [1].